ME01510B - MIPO INHIBITORI ZA TRETIRANJE HUNTINGTONOVE BOLESTI l MULTIPLE SISTEMSKE ATROFIJE - Google Patents

MIPO INHIBITORI ZA TRETIRANJE HUNTINGTONOVE BOLESTI l MULTIPLE SISTEMSKE ATROFIJE

Info

Publication number
ME01510B
ME01510B MEP-2013-49A MEP4913A ME01510B ME 01510 B ME01510 B ME 01510B ME P4913 A MEP4913 A ME P4913A ME 01510 B ME01510 B ME 01510B
Authority
ME
Montenegro
Prior art keywords
treatment
huntington
disease
mipo
inhibitors
Prior art date
Application number
MEP-2013-49A
Other languages
English (en)
Unknown language (me)
Inventor
Håkan Eriksson
Werner Poewe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ME01510B publication Critical patent/ME01510B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-2013-49A 2007-08-23 2008-08-22 MIPO INHIBITORI ZA TRETIRANJE HUNTINGTONOVE BOLESTI l MULTIPLE SISTEMSKE ATROFIJE ME01510B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95752507P 2007-08-23 2007-08-23
US95752307P 2007-08-23 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
EP08794174A EP2200616B1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Publications (1)

Publication Number Publication Date
ME01510B true ME01510B (me) 2014-04-20

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2013-49A ME01510B (me) 2007-08-23 2008-08-22 MIPO INHIBITORI ZA TRETIRANJE HUNTINGTONOVE BOLESTI l MULTIPLE SISTEMSKE ATROFIJE

Country Status (25)

Country Link
US (6) US20090054468A1 (OSRAM)
EP (1) EP2200616B1 (OSRAM)
JP (2) JP5247804B2 (OSRAM)
KR (1) KR101588464B1 (OSRAM)
CN (4) CN105687199A (OSRAM)
AU (1) AU2008289653B2 (OSRAM)
BR (1) BRPI0815681A2 (OSRAM)
CA (1) CA2698205C (OSRAM)
CY (1) CY1113714T1 (OSRAM)
DK (1) DK2200616T3 (OSRAM)
EA (1) EA017510B1 (OSRAM)
ES (1) ES2399846T3 (OSRAM)
HR (1) HRP20130139T1 (OSRAM)
IL (2) IL203738A (OSRAM)
ME (1) ME01510B (OSRAM)
MX (1) MX2010001983A (OSRAM)
MY (1) MY155633A (OSRAM)
NZ (1) NZ584135A (OSRAM)
PH (1) PH12014501180A1 (OSRAM)
PL (1) PL2200616T3 (OSRAM)
PT (1) PT2200616E (OSRAM)
RS (1) RS52665B (OSRAM)
SI (1) SI2200616T1 (OSRAM)
WO (1) WO2009025618A1 (OSRAM)
ZA (1) ZA201000848B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2776405A1 (en) 2011-11-11 2014-09-17 Pfizer Inc 2-thiopyrimidinones
WO2013144088A1 (en) * 2012-03-29 2013-10-03 Basf Se N-substituted hetero-bicyclic compounds and derivatives for combating animal pests ii
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
MX382097B (es) 2015-05-05 2025-03-13 Pfizer 1-(2-aminoetil)-6-(2-(2-hidroxietoxi)-5-metilfenil)-2-tioxo-2,3-dihidropirimidin-4(1h)-ona, y el uso del mismo para tratar afecciones cardiovasculares.
CN111182898B (zh) * 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
KR102705858B1 (ko) * 2017-07-17 2024-09-10 아스트라제네카 아베 의약에서의 사용을 위한 mpo 억제제
US20240067651A1 (en) * 2019-10-10 2024-02-29 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
KR20220149709A (ko) * 2020-03-05 2022-11-08 바이오하벤 테라퓨틱스 리미티드 골수 세포형과산화효소 저해제를 사용한 근위축성 측삭 경화증의 치료 방법
IL297857A (en) * 2020-05-06 2023-01-01 Biohaven Therapeutics Ltd Process for the preparation of verdiperstat
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
TW202426450A (zh) 2022-08-18 2024-07-01 瑞典商阿斯特捷利康公司 髓過氧化物酶抑制劑
WO2024047094A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab Pharmaceutical formulation
EP4624473A1 (en) * 2022-12-09 2025-10-01 Shenzhen Salubris Pharmaceuticals Co., Ltd. Pyrrolo[3,2-d]pyrimidin-4-one derivative, and preparation method therefor and medical use thereof
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
US20040198753A1 (en) * 2002-01-28 2004-10-07 Hiroshi Kase Methods of treating patients suffering from movement disorders
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
EP2029603A1 (en) * 2006-06-05 2009-03-04 Astra Zeneca AB Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
CN105687199A (zh) 2016-06-22
CN103638029A (zh) 2014-03-19
CN101873857A (zh) 2010-10-27
US10772890B2 (en) 2020-09-15
CA2698205C (en) 2016-06-21
CN113633641A (zh) 2021-11-12
US20190099423A1 (en) 2019-04-04
ES2399846T3 (es) 2013-04-03
JP2013151547A (ja) 2013-08-08
MX2010001983A (es) 2010-03-10
DK2200616T3 (da) 2013-03-04
ZA201000848B (en) 2012-07-25
WO2009025618A1 (en) 2009-02-26
JP5247804B2 (ja) 2013-07-24
BRPI0815681A2 (pt) 2015-02-18
PH12014501180A1 (en) 2015-08-24
EA017510B1 (ru) 2013-01-30
KR20100055434A (ko) 2010-05-26
CY1113714T1 (el) 2016-06-22
US20130059870A1 (en) 2013-03-07
US20140221400A1 (en) 2014-08-07
PL2200616T3 (pl) 2013-04-30
EP2200616A1 (en) 2010-06-30
KR101588464B1 (ko) 2016-01-25
CA2698205A1 (en) 2009-02-26
MY155633A (en) 2015-11-13
EA201000202A1 (ru) 2010-10-29
US20090054468A1 (en) 2009-02-26
IL240130A0 (en) 2015-09-24
SI2200616T1 (sl) 2013-03-29
AU2008289653A1 (en) 2009-02-26
RS52665B (sr) 2013-06-28
HRP20130139T1 (hr) 2013-03-31
HK1145141A1 (en) 2011-04-08
EP2200616A4 (en) 2010-08-25
IL203738A (en) 2015-08-31
JP2010536849A (ja) 2010-12-02
AU2008289653B2 (en) 2012-06-28
NZ584135A (en) 2012-04-27
PT2200616E (pt) 2013-02-27
US20110207755A1 (en) 2011-08-25
EP2200616B1 (en) 2012-12-26
US20200405724A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
ME01510B (me) MIPO INHIBITORI ZA TRETIRANJE HUNTINGTONOVE BOLESTI l MULTIPLE SISTEMSKE ATROFIJE
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
PA8836101A1 (es) Inhibidores alfa7 nicotínicos del receptor de acetilcolina
MX388981B (es) Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
NI200900170A (es) Derivados de isoindolina 4' - o - sustituidos y composiciones que los comprenden y métodos para usar los mismos.
CY1116377T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης
ECSP088972A (es) Isoindoles sustituidos como inhibidores de bace y su uso
CL2008002089A1 (es) Compuesto para la regeneracion de tejidos que comprende al menos una sustancia derivada de sangre y acido hialuronico y/o al menos un compuesto derivado de acido hialuronico; metodo para la prepararcion de dicho compuesto.
HN2011001446A (es) Compuesto utiles para inhibir chk1
ES2563777T3 (es) Compuestos de nitrona para tratar la pérdida auditiva sensorineural
BR112015021147A2 (pt) métodos e detergentes enzimáticos para remoção de biomembranas
MX2007012732A (es) Derivados de azol en forma de inhibidores de lipasas y fosfolipasas.
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
MA31305B1 (fr) Administration hebdomadaire d'inhibiteurs de la dipeptidyle peptidase
UY31771A1 (es) Inhibidores de catepsina c
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
CR10422A (es) Formulaciones de dosificacion solida
SG132661A1 (en) Illumination system
AR063027A1 (es) Derivados de sulfonamida
FR2901467B1 (fr) Prothese anatomique pour le traitement des hernies, telles que hernies inguinales et crurales et autres
CO6400226A2 (es) Micrólido anti-inflamatorio
CL2009001192A1 (es) Compuestos derivados de 2-(4-carboxiciclohexilamino)-4-(1-indolil)pirimidina, inhibidores de jnk; proceso de preparacion; composicion farmaceutica que los comprende; y su uso para tratar o prevenir trastornos autoinmunes, inflamatorios, metabolicos, enfermedad neurologica, cancer.
BR112022006381A2 (pt) Pró-fármacos de inibidores de mieloperoxidase
EP2007372A4 (en) Dialkyl-ABAGBEWIRKSTOFFE